Acumen Pharmaceuticals ABOS 深 沪
等待开盘 08-08 09:30:00 美东时间
1.42
+0.020
+1.43%
华盛通- 最 高1.47
- 今 开1.40
- 成交量 31.86万股
- 最 低 1.3701
- 昨 收 1.40
- 总市值 8601.42万
- 52周最高 3.36
- 市盈率 静 --
- 换手率 0.53%
- 52周最低 0.8551
- 委 比 68.66%
- 总股本 6057.34万
- 历史最高 26.98
- 量 比 1.80
- 振 幅 7.14%
- 历史最低 0.8551
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease, announced it will report second quarter 2025 financial results on August 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. Registration for the call is required in advance. The webcast will al...
08-05 20:00
快讯 | Acumen制药公司与Jcr制药公司签署战略合作、选项和许可协议，共同开发增强型脑部输送™疗法治疗阿尔茨海默病
Acumen Pharmaceuticals and Jcr Pharmaceuticals Enter Strategic Collaboration, O...
07-15 19:00
快讯 | Acumen制药公司 - 预计2026年初发布阿尔茨海默病治疗的临床前数据
Acumen Pharmaceuticals Inc - Preclinical Data Expected in Early 2026 for Alzhei...
07-15 19:00
快讯 | Acumen制药公司 - Jcr将从Acumen收到预付款和选项付款
Acumen Pharmaceuticals Inc - Jcr to Receive Upfront and Option Payments From Ac...
07-15 19:00
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Acumen Pharmaceuticals and JCR Pharmaceuticals have entered a collaboration to develop a novel Alzheimer's disease therapy combining Acumen's amyloid beta oligomer-selective antibody expertise with JCR's transferrin-receptor-targeting blood-brain barrier technology. Preclinical candidate data is expected early in 2026, with Acumen having an exclusive option to develop up to two candidates. This partnership aims to enhance therapeutic efficacy, sa...
07-15 11:00
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
Acumen Pharmaceuticals will present new findings on its Alzheimer’s disease therapy sabirnetug at AAIC 2025 in Toronto, including a cost savings analysis using pTau217 in its Phase 2 trial and a study on the antibody's selectivity for amyloid beta oligomers. The presentations highlight the potential of biomarker-driven screening and targeted therapeutics in improving trial efficiency and patient care. Sabirnetug, which targets toxic amyloid beta ...
07-10 12:00
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective aft...
07-01 04:05
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $4
Citigroup analyst Geoff Meacham initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announces Price Target of $4.
06-17 19:34
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to ...
05-29 04:05
